XNK Therapeutics AB ayaa maanta ku dhawaaqday in bukaankii ugu horreeyay lagu daaweeyay daraasadda bukaan-socodka ee Wajiga II iyadoo la adeegsanayo daawada musharraxa ee hormuudka u ah difaaca dabiiciga ah ee XNK (NK) oo ay weheliso Sanofi's anti-CD38 antibody Sarclisa (Isatuximab).
"Inaad haysato bukaan-socodka ugu horreeya ee lagu daweeyo unugyada NK ee daraasaddan bukaan-socodka ah ayaa ah mid muhiim u ah horumarinta bukaan-socodka ee musharraxa musharraxa daroogada," ayuu yiri Johan Aschan, CMO ee XNK Therapeutics. "Daraasadda ayaa si wanaagsan u socota, waxaana rajeyneynaa natiijada."
Baaraha hadda jira-bilabay, furan, randomized, la xakameeyey, heerka II daraasaadka ISA-HC-NK (EudraCT: 2020-000994-26) isbarbardhigga daroogada musharax ee XNK oo ay weheliso Sanofi's anti-CD38 antibody Isatuximab iyo Isatuximab oo keliya sida daawaynta xoojinta ka dib. Ku-tallaalidda unugga stem autologous ee bukaannada qaba myeloma badan oo dhawaan laga helay. Daraasadda caafimaadku waxay ka dhacdaa cusbitaalka jaamacadda Karolinska ee ku yaal goobta Huddinge waxayna ka kooban tahay 60 bukaan oo ay 30 bukaan ku jiraan cudud kasta.
